Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AES Corp (AES) vs Mesoblast Limited (MESO) Price & Performance

Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

AES Corp vs Mesoblast Limited — how do they compare? AES Corp trades at $14.72 (market cap $10.51B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: AES Corp is far larger — about 4.9× Mesoblast Limited's market cap, and AES Corp pays a 4.78% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.

AESMESO
Market Cap
$10.51B$2.16B
Sector
UtilitiesTechnology
52-Week High
$17.28$20.96
52-Week Low
$12.51$12.88
Enterprise Value
$40.77B$2.17B
Dividend Yield
4.78%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AES Corp

AES trades at $14.73, up 0.2% on the day, with a bullish technical signal supported by moving averages. The company reported strong profitability with a net income margin of 14.34% and ROE of 45.05% for 2025, though Q2 2026 EPS missed expectations. A pending $33.4 billion acquisition by a consortium led by Global Infrastructure Partners and EQT, approved by stockholders, dominates recent developments, alongside a consistent dividend payout.

The acquisition offers a near-term catalyst with a capped upside at the buyout price of $15 per share, presenting a low-risk arbitrage opportunity. Risks include deal completion uncertainty amid shareholder complaints and regulatory scrutiny. Analyst consensus is mixed with 43% buy ratings, reflecting cautious optimism tied to the acquisition's successful closure and the company's strategic shift toward renewable energy investments.

Mesoblast Limited

MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.

Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.

Returns comparison

Trailing returns across standard periods

About AES Corp

AES is a global power company operating across 14 countries and 4 continents. Its current generation portfolio as of year-end 2021 consists of over 31 gigawatts of generation, with the generation mix composed of renewables (43%), gas (32%), coal (23%), and oil (2%). The company has 3.5 gigawatts of generation under construction. AES has majority ownership and operates six electric utilities distributing power to 2.6 million customers.

Read more on AES

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO